Skip to main content

Table 1 Clinicopathological characteristics of patients

From: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

Characteristic

N (%)

Total

58 (100)

Pre-neoadjuvant TIL evaluation available

43 (74.1)

Post-neoadjuvant TIL evaluation available

58 (100)

Age (range 28–71 years)

 <50 years

28 (48.2)

 ≥50 years

30 (51.7)

Histotype

 Ductal

50 (86)

 Other

8 (3)

 DCIS foci

8 (13.7)

ER

 Negative

12 (20.6)

 Positive

45 (77.5)

 TNBC

9 (15.5)

PR

 Negative

17 (29.3)

 Positive

40 (68.9)

HER2

 Negative

46 (79.3)

 Positive

12 (20.6)

Lymph node status

 Negative

21 (36.2)

 Positive

37 (63.7)

Residual tumor size

 <2 cm

24 (41.3)

  > 2 cm

34 (58.6)

Grade at diagnosis

 1 and 2

37 (63.7)

 3

19 (32.75)

 N/A

2 (0.034)

Relapse

 No relapse

25 (43.1)

 Relapse

11 (18.9)

 N/A

22 (37.9)

Neoadjuvant chemotherapy

 AC/taxane

33 (56.8)

 Other

25 (43.1)

  1. TIL tumor infiltrating lymphocyte, DCIS ductal carcinoma in situ, ER estrogen receptor, TNBC triple-negative breast cancer, PR progesterone receptor, HER human epidermal growth factor, AC anthracycline, N/A not available